As of 2015 June, the newly established Alvogen Korea will advance as One Team, with One Vision, creating synergy with the foundation of trust that the two companies have built over the years in the pharmaceutical industry. The consolidation will be the base for a strong platform for growth not only in Korean market but also in APAC market to achieve Alvogen’s stated ambition of becoming one of the top 5 regional players in APAC market.
Alvogen Korea is a prominent leader in the Korean anti-obesity market with strong competitive edge, and at the same time, it owns broad portfolio of therapeutic products such as oncology, CNS, nephrology, cardiology, anti-virus and urology. Also, along with the recent development of incrementally modified drugs, Alvogen intends to consistantly launch marketable and differentiated products.
Kunwha Pharmaceuticals today announces that it will trade as Alvogen Korea from June 2015. The decision follows the Company’s recent merger with Dream Pharma, a market leader in the Korean anti-obesity market.